Comparison of plasma concentrations of levobupivacaine with and without epinephrine for thoracic paravertebral block

Acronym

Comparison of plasma concentrations of levobupivacaine with and without epinephrine for thoracic paravertebral block

Scientific Title

Comparison of plasma concentrations of levobupivacaine with and without epinephrine for thoracic paravertebral block

Scientific Title:Acronym

Comparison of plasma concentrations of levobupivacaine with and without epinephrine for thoracic paravertebral block

Region

Japan

Condition

Condition

Patients who were scheduled to undergo elective unilateral pulmonary lobectomy or segmentectomy under general anesthesia combined with thoracic paravertebral block for a lung cancer.

Classification by specialty

Chest surgery

Anesthesiology

Classification by malignancy

Malignancy

Genomic information

NO

Objectives

Narrative objectives1

We studied the pharmacokinetics for levobupivacaine after thoracic paravertebral block and the effect of addition of epinephrine on plasma concentrations of levobupivacaine.

Basic objectives2

Safety,Efficacy

Basic objectives -Others

Trial characteristics_1

Trial characteristics_2

Developmental phase

Not applicable

Assessment

Primary outcomes

The plasma concentration of levobupivacaine was measured at 1, 2.5, 5, 7.5, 10, 12.5, 15, 20, 30, 45, 60, 90, 120 and 150 minutes after paravertebral block. The peak plasma concentration and the time to peak plasma concentration for levobupivacaine were recorded directly from the measured values. The area under the plasma concentration time curve was calculated using the trapezoidal rule.

Key secondary outcomes

Pain:Numerical Rating Scale at rest and at cough after 6,12, 24, 48, and 72 hours postoperation.

1)Patients who are scheduled for unilateral pulmonary lobectomy or segmentectomy under general anesthesia combined with thoracic paravertebral block in Wakayama medical university hospital.
2)American Society of Anethesiologists physical status in 1, 2 or 3.
3)Patients who can give written informed consent.

Key exclusion criteria

1)Patients who have contraindication of thoracic paravertebral block.
2)Patients who have allergy to the drugs which will going to use in this trial.
3)Patients who are regarded ineligible by doctors with ather reasons.